BPH Energy Limited
AASX:BPH0.00
AUD
+0.00
(-33.33%)
BPH Energy Limited
ASX:BPH
(Australian Securities Exchange)
Recent
price
0.00
P/E
ratio
1.42
div
yld
- -
ROIC.AI
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.- Similar Companies
- Business
- BPH Energy Limited (ASX:BPH) is an Australia-based diversified investment company focused on biotechnology and resources sectors; it holds a 36% interest in unlisted oil and gas explorer Advent Energy Ltd, commercializes a portfolio of biomedical technologies from collaborative research by Australian universities, medical institutes, and hospitals including The Harry Perkins Institute for Medical Research and Swinburne University of Technology, and invests in clean hydrogen production technologies. The company provides early-stage funding, project management, and commercialization strategies for biomedical innovations through direct collaborations, spin-out companies, or licensing arrangements; in resources, it supports oil and gas exploration and development primarily via Advent Energy's offshore permits such as PEP-11 in the Sydney Basin, which holds prospective resources of 5.7 trillion cubic feet of gas equivalent. Founded in 2001 and headquartered at 114 Cedric Street, Stirling, Western Australia, BPH operates principally in Australia with investments targeting domestic energy security and global clean energy transitions. Recent developments include ongoing judicial proceedings for the PEP-11 Joint Venture with Bounty Oil & Gas NL (ASX:BUY), where a hearing commenced in September 2025 under Justice Jackson following an Originating Application filed in August 2024; progression of Clean Hydrogen Technologies (16.2% interest) toward pilot plants in the USA and India using thermo-catalytic pyrolysis for zero-CO2 hydrogen and solid carbon from natural gas; and strong FY2025 financial results with net profit up 49% to A$6.8 million. In FY2025, investee Cortical Dynamics advanced its BARM brain anaesthesia monitoring system with FDA 510(k) clearance for version 1 and initiation of clinical trials for AI-enhanced BARM 2.0; BPH also completed placements including options approved in October 2024 to fund hydrocarbon and hydrogen projects.